Interactive Financial Charts Not Available

Sinovac Biotech (SVA) | Financial Analysis & Statements

Sinovac Biotech Ltd. | Small-cap

$6.47

0.00%

Sinovac Biotech vs Coursera Sinovac Biotech vs Teradata Sinovac Biotech vs W.K. Kellogg Sinovac Biotech vs Ingevity Sinovac Biotech vs Adaptive Sinovac Biotech vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Dec 2020

Income Metrics

Revenue 327.5M

Gross Profit 283.9M 86.71%

Operating Income 197.0M 60.17%

Net Income 172.7M 52.74%

EPS (Diluted) $0.96

Balance Sheet Metrics

Total Assets 13.7B

Total Liabilities 1.6B

Shareholders Equity 12.0B

Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow 455.2M

Free Cash Flow 423.2M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Sinovac Biotech Income Statement From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Revenue i	448.3M	1.5B	19.4B	510.6M	246.1M
Cost of Goods Sold i	181.5M	684.5M	1.1B	67.2M	32.5M
Gross Profit i	266.8M	808.3M	18.3B	443.4M	213.6M
Gross Margin % i	59.5%	54.1%	94.5%	86.8%	86.8%
Operating Expenses
Research & Development i	344.5M	442.1M	155.0M	48.8M	24.3M
Selling, General & Administrative i	466.3M	823.5M	591.2M	176.5M	121.5M
Other Operating Expenses i	-22.4M	-760.0K	-725.0K	-297.0K	-688.0K
Total Operating Expenses i	788.4M	1.3B	745.5M	225.0M	145.0M
Operating Income i	-524.3M	-460.9M	17.6B	215.8M	68.9M
Operating Margin % i	-117.0%	-30.9%	90.6%	42.3%	28.0%
Non-Operating Items
Interest Income i	85.1M	190.8M	102.6M	1.9M	2.0M
Interest Expense i	2.3M	1.3M	2.8M	1.5M	650.0K
Other Non-Operating Income	288.4M	296.5M	-90.9M	333.0K	618.0K
Pre-tax Income i	-153.0M	25.2M	17.6B	216.6M	70.8M
Income Tax i	105.3M	-62.9M	3.1B	31.4M	5.6M
Effective Tax Rate % i	0.0%	-249.2%	17.7%	14.5%	7.9%
Net Income i	-258.4M	88.1M	14.5B	185.2M	65.2M
Net Margin % i	-57.6%	5.9%	74.6%	36.3%	26.5%
Key Metrics
EBITDA i	72.7M	188.3M	17.7B	222.3M	76.6M
EPS (Basic) i	$-1.06	$1.08	$85.20	$1.06	$0.42
EPS (Diluted) i	$-1.06	$1.00	$74.27	$0.97	$0.41
Basic Shares Outstanding i	99607574	99502243	99311551	98897345	94876946
Diluted Shares Outstanding i	99607574	99502243	99311551	98897345	94876946

Income Statement Trend

Sinovac Biotech Balance Sheet From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Assets
Current Assets
Cash & Equivalents i	1.3B	4.3B	11.6B	1.0B	152.7M
Short-term Investments i	10.0B	7.0B	1.8B	135.2M	50.3M
Accounts Receivable i	426.0M	497.0M	923.8M	250.6M	112.1M
Inventory i	139.9M	180.7M	375.5M	105.8M	27.8M
Other Current Assets	-	-	-	-	-
Total Current Assets i	11.8B	12.1B	14.9B	1.6B	349.6M
Non-Current Assets
Property, Plant & Equipment i	45.5M	58.6M	115.4M	83.8M	6.6M
Goodwill i	74.1M	79.5M	41.2M	9.7M	8.0M
Intangible Assets i	74.1M	79.5M	41.2M	9.7M	8.0M
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	37.1M	73.9M	52.0M	26.9M	11.4M
Total Non-Current Assets i	1.8B	2.0B	1.8B	341.0M	102.7M
Total Assets i	13.7B	14.1B	16.7B	1.9B	452.3M
Liabilities
Current Liabilities
Accounts Payable i	17.3M	19.8M	58.6M	30.5M	5.8M
Short-term Debt i	81.9M	10.6M	15.1M	42.6M	13.1M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities i	1.1B	1.1B	2.4B	679.6M	87.2M
Non-Current Liabilities
Long-term Debt i	217.1M	64.0M	129.8M	93.8M	7.2M
Deferred Tax Liabilities i	263.7M	241.5M	324.2M	2.7M	0
Other Non-Current Liabilities	439.0K	240.0K	444.0K	865.0K	1.7M
Total Non-Current Liabilities i	487.3M	310.3M	459.3M	101.6M	12.9M
Total Liabilities i	1.6B	1.4B	2.9B	781.2M	100.1M
Equity
Common Stock i	100.0K	100.0K	100.0K	99.0K	99.0K
Retained Earnings i	7.1B	7.2B	7.1B	144.2M	56.7M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	12.0B	12.7B	13.9B	1.1B	352.2M
Key Metrics
Total Debt i	299.0M	74.7M	144.9M	136.4M	20.3M
Working Capital i	10.7B	11.0B	12.5B	880.7M	262.4M

Balance Sheet Composition

Sinovac Biotech Cash Flow Statement From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Operating Activities
Net Income i	-258.4M	88.1M	14.5B	185.2M	65.2M
Depreciation & Amortization i	144.7M	156.6M	86.8M	4.0M	4.8M
Stock-Based Compensation i	0	0	7.7M	10.2M	3.0M
Working Capital Changes i	173.3M	171.6M	-612.8M	295.9M	-35.8M
Operating Cash Flow i	113.6M	332.5M	14.2B	483.8M	30.9M
Investing Activities
Capital Expenditures i	-144.5M	-393.2M	-719.7M	-127.5M	-10.6M
Acquisitions i	-131.7M	8.9M	-13.7M	0	0
Investment Purchases i	-8.2B	-11.7B	-8.8B	-201.7M	-50.7M
Investment Sales i	5.6B	6.3B	6.6B	124.6M	18.8M
Investing Cash Flow i	-2.9B	-5.8B	-3.0B	-204.6M	-42.5M
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-328.1M	-263.2M	-1.9B	0	0
Debt Issuance i	243.4M	151.0K	20.6M	43.4M	3.6M
Debt Repayment i	-4.6M	-4.5M	-46.8M	-10.4M	-3.3M
Financing Cash Flow i	-76.1M	-241.4M	-1.9B	592.6M	1.7M
Free Cash Flow i	-41.7M	-1.2B	14.6B	351.7M	28.4M
Net Change in Cash i	-2.9B	-5.7B	9.3B	871.8M	-9.8M

Cash Flow Trend

Sinovac Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 6.66

Forward P/E -53.92

Price to Book 0.05

Price to Sales 1.43

PEG Ratio 0.02

Profitability Ratios

Profit Margin 59.51%

Operating Margin -33.63%

Return on Equity -0.88%

Return on Assets -0.78%

Financial Health

Current Ratio 10.31

Debt to Equity 0.02

Per Share Data

EPS (TTM) $-1.06

Book Value per Share $121.57

Revenue per Share $4.50

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
sva	642.4M	6.66	0.05	-0.88%	59.51%	0.02
Coursera	2.0B	-24.25	3.31	-10.83%	-9.37%	0.51
Teradata	2.0B	18.65	11.34	87.65%	6.57%	331.25
W.K. Kellogg	2.0B	67.65	5.75	8.81%	1.15%	249.57
Ingevity	2.0B	12.96	16.67	-106.83%	-16.35%	1,139.77
Adaptive	2.0B	-12.07	11.04	-57.60%	-59.07%	121.39

Financial data is updated regularly. All figures are in the company's reporting currency.